JP5894935B2 - サングリフェリン系化合物 - Google Patents

サングリフェリン系化合物 Download PDF

Info

Publication number
JP5894935B2
JP5894935B2 JP2012552469A JP2012552469A JP5894935B2 JP 5894935 B2 JP5894935 B2 JP 5894935B2 JP 2012552469 A JP2012552469 A JP 2012552469A JP 2012552469 A JP2012552469 A JP 2012552469A JP 5894935 B2 JP5894935 B2 JP 5894935B2
Authority
JP
Japan
Prior art keywords
single bond
represented
bond
structure below
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012552469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518923A5 (OSRAM
JP2013518923A (ja
Inventor
ジャメス モスス ステベン
ジャメス モスス ステベン
アラン グレゴリ マトトヘウ
アラン グレゴリ マトトヘウ
ウイルキンソン バルリエ
ウイルキンソン バルリエ
ジャネト マルトイン クフリストイネ
ジャネト マルトイン クフリストイネ
Original Assignee
ニューロヴィベ プハルマセウトイカル エービー
ニューロヴィベ プハルマセウトイカル エービー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1002097.2A external-priority patent/GB201002097D0/en
Priority claimed from GBGB1006128.1A external-priority patent/GB201006128D0/en
Priority claimed from GBGB1101085.7A external-priority patent/GB201101085D0/en
Application filed by ニューロヴィベ プハルマセウトイカル エービー, ニューロヴィベ プハルマセウトイカル エービー filed Critical ニューロヴィベ プハルマセウトイカル エービー
Publication of JP2013518923A publication Critical patent/JP2013518923A/ja
Publication of JP2013518923A5 publication Critical patent/JP2013518923A5/ja
Application granted granted Critical
Publication of JP5894935B2 publication Critical patent/JP5894935B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
JP2012552469A 2010-02-09 2011-02-09 サングリフェリン系化合物 Expired - Fee Related JP5894935B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1002097.2A GB201002097D0 (en) 2010-02-09 2010-02-09 Novel compounds
GB1002097.2 2010-02-09
GB1006128.1 2010-04-13
GBGB1006128.1A GB201006128D0 (en) 2010-04-13 2010-04-13 Novel compounds
GBGB1101085.7A GB201101085D0 (en) 2011-01-21 2011-01-21 Novel compounds
GB1101085.7 2011-01-21
PCT/GB2011/050236 WO2011098809A1 (en) 2010-02-09 2011-02-09 Sanglifehrin based compounds

Publications (3)

Publication Number Publication Date
JP2013518923A JP2013518923A (ja) 2013-05-23
JP2013518923A5 JP2013518923A5 (OSRAM) 2015-11-19
JP5894935B2 true JP5894935B2 (ja) 2016-03-30

Family

ID=43836693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012552469A Expired - Fee Related JP5894935B2 (ja) 2010-02-09 2011-02-09 サングリフェリン系化合物

Country Status (9)

Country Link
US (1) US9119853B2 (OSRAM)
EP (1) EP2533784B1 (OSRAM)
JP (1) JP5894935B2 (OSRAM)
AU (1) AU2011214135B2 (OSRAM)
BR (1) BR112012019866A8 (OSRAM)
CA (1) CA2788761C (OSRAM)
ES (1) ES2541853T3 (OSRAM)
MX (1) MX2012008873A (OSRAM)
WO (1) WO2011098809A1 (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201008123D0 (en) * 2010-05-17 2010-06-30 Biotica Tech Ltd Novel compounds
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
GB201118334D0 (en) * 2011-10-24 2011-12-07 Biotica Tech Ltd Novel dosage form
BR112019009903A2 (pt) 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b
AU2019401466B2 (en) * 2018-12-21 2025-04-24 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
DK0909327T3 (da) 1996-07-05 2005-09-26 Biotica Tech Ltd Erythromyciner og fremgangsmåder til deres fremstilling
GB9814622D0 (en) 1998-07-06 1998-09-02 Biotica Tech Ltd Polyketides,their preparation,and materials for use therein
CN101242842A (zh) 2005-06-17 2008-08-13 诺瓦提斯公司 Sanglifehrin在hcv中的用途
EP2124992A2 (en) 2007-01-04 2009-12-02 Debiopharm S.A. Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy
US8962329B2 (en) 2008-09-24 2015-02-24 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Gene cluster
JO3063B1 (ar) 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
BR112012019866A8 (pt) 2017-12-26
BR112012019866A2 (pt) 2017-07-11
EP2533784A1 (en) 2012-12-19
AU2011214135B2 (en) 2014-07-31
WO2011098809A1 (en) 2011-08-18
US9119853B2 (en) 2015-09-01
CA2788761C (en) 2018-05-29
CA2788761A1 (en) 2011-08-18
EP2533784B1 (en) 2015-04-22
MX2012008873A (es) 2012-11-22
US20120295841A1 (en) 2012-11-22
CN102770139A (zh) 2012-11-07
AU2011214135A1 (en) 2012-08-23
JP2013518923A (ja) 2013-05-23
ES2541853T3 (es) 2015-07-27

Similar Documents

Publication Publication Date Title
JP5894935B2 (ja) サングリフェリン系化合物
JP6118793B2 (ja) マクロ環状化合物及びそれらの製造方法
WO2011098808A1 (en) Sanglifehrin based compounds
JP6293852B2 (ja) サングリフェリン誘導体及びそれらの製造方法
WO2011098805A1 (en) Sanglifehrin based compounds
CN102770139B (zh) 基于Sanglifehrin的化合物
Class et al. Patent application title: Macrocyclic Compounds and Methods for Their Production Inventors: Steven James Moss (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Matthew Alan Gregory (Cambridge, GB) Barrie Wilkinson (Cambridge, GB) Assignees: NeuroVive Pharmaceutical AB
HK1189237B (en) Macrocyclic compounds and methods for their production

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150924

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160229

R150 Certificate of patent or registration of utility model

Ref document number: 5894935

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees